Rogler Gerhard
Klinik für Gastroenterologie und Hepatologie, Universitätsspital Zürich, Rämistrasse 100, 8091, Zürich, Schweiz.
Inn Med (Heidelb). 2025 Jan;66(1):15-21. doi: 10.1007/s00108-024-01840-x. Epub 2024 Dec 23.
The cornerstone of treatment for mild ulcerative colitis is still the oral or topical (rectal) application of aminosalicylates (5-ASA). 5‑ASA preparations are often only administered orally in mild ulcerative colitis. Study data show that in ulcerative proctitis and left-sided colitis, rectal 5‑ASA preparations are even more effective than oral administration. In a next step, steroid-containing topical therapies should be used. Topical steroids such as budesonide are also primarily used in mild Crohn's disease. However, it is controversial whether treatment is necessary in symptom-free patients. There is still a lack of evidence to prove that more aggressive treatment (using immunosuppressants, biologics or small molecules) has a long-term benefit in these patients. Most guidelines are critical of the use of 5‑ASA in mild Crohn's disease. Nevertheless, there is some evidence for sufficiently high-dose treatment with 5‑ASA, although one must be aware of its limited effectiveness. However, there is clear evidence for the postoperative use of 5‑ASA in cases of mild recurrence.
轻度溃疡性结肠炎的治疗基石仍然是口服或局部(直肠)应用氨基水杨酸酯(5-ASA)。在轻度溃疡性结肠炎中,5-ASA制剂通常仅口服给药。研究数据表明,在溃疡性直肠炎和左侧结肠炎中,直肠用5-ASA制剂比口服给药更有效。下一步应使用含类固醇的局部治疗。布地奈德等局部类固醇也主要用于轻度克罗恩病。然而,无症状患者是否需要治疗存在争议。仍然缺乏证据证明更积极的治疗(使用免疫抑制剂、生物制剂或小分子药物)对这些患者有长期益处。大多数指南对在轻度克罗恩病中使用5-ASA持批评态度。尽管如此,有一些证据支持用足够高剂量的5-ASA进行治疗,不过必须意识到其有效性有限。然而,有明确证据表明在轻度复发的情况下术后使用5-ASA。